newsfilter
← Latest News
GlobeNewswire·

Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan

  • Serina Therapeutics announced that NYSE American has accepted its business plan to regain compliance with continued listing standards.
  • The company previously received a non-compliance notice on January 9, 2026, due to $1.6 million in stockholders' equity & losses in three of the four most recent fiscal years.
  • Serina has until July 9, 2027, to meet the required listing standards while remaining listed on NYSE American subject to other rules.
  • The company will undergo quarterly monitoring by NYSE American to track progress against the compliance plan.
  • Failure to comply with the plan or meet listing standards by the deadline will trigger suspension & delisting procedures.
  • Serina is a clinical-stage biotechnology firm headquartered in Huntsville, Alabama, focused on neurological diseases using its proprietary POZ Platform.
  • The company is advancing its SER-252 clinical program & continues to develop its drug optimization technology.